Cellect to develop stem cell therapy for COVID-19

By The Science Advisory Board staff writers

May 18, 2020 -- Cellect Biotechnology has inked an agreement with international collaborators to develop a stem cell therapy for COVID-19 disease.

Under the agreement, the company will investigate the therapeutic effects of ApoGraft-treated stem cells to reduce pulmonary manifestations of COVID-19. ApoGraft has been used in clinical trials with graft versus host disease and mesenchymal stem cells; its anti-graft versus host disease effects may be able to address cytokine storms seen in COVID-19 patients as well as other medical conditions like CAR-T cell adverse effects, according to the firm.

The agreement allows for the firm to leverage its ApoGraft clinical data and regulatory approvals to expedite the cytokine storm therapy for COVID-19 as well as CAR-T related cytokine storm conditions. The firm has completed the technology and material transfer and is currently conducting preclinical studies related to COVID-19.

Nasal, oral antiseptics show antiviral activity against SARS-CoV-2
Veloce BioPharma has reported that its nasal and oral antiseptics are effective against SARS-CoV-2, the virus responsible for COVID-19.
Are interferons a viable therapeutic intervention for COVID-19?
Significantly improved viral clearance and reductions in inflammatory cytokines are observed in COVID-19 patients treated with interferons, according...
Avacta's Affimer reagent may neutralize SARS-CoV-2
Avacta Group, the developer of Affimer biotherapeutics and reagents, announced that several Affimer reagents block the interaction between SARS-CoV-2's...
Proteomics provides insights into SARS-CoV-2 infection, potential therapies
Scientists tested a series of compounds for blocking the replication of SARS-CoV-2 using a novel proteomics approach. The method, which helped identify...
Exyte, Univercells fast track construction for COVID-19 vaccines
High-tech construction firm Exyte and biomanufacturing company Univercells Technologies are partnering for construction of modular standardized and flexible...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter